HPB-092

HPB-092 is an orally administered, small molecule dual inhibitor of **Fms-like tyrosine kinase 3 (FLT3)** and **Interleukin-1 receptor-associated kinase 4 (IRAK4)** developed for the treatment of relapsed and refractory acute myeloid leukemia (RR-AML)[1][2][3][5]. By targeting both FLT3 mutants (with potency comparable or superior to approved FLT3 inhibitors) and IRAK4 (particularly the long isoform, IRAK4-L, associated with poor AML prognosis and resistance to FLT3 inhibitors), HPB-092 aims to improve therapeutic outcomes and reduce resistance in AML patients. It exhibits high selectivity, favorable pharmacokinetics, low CYP3A4 inhibition, no hERG activity, and a broad safety window in preclinical models. HPB-092 is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in adults with RR-AML, especially those with FLT3, U2AF1, or SF3B1 mutations[1][2][3]. The developer is Hangzhou Polymed Biopharmaceuticals.